After few decades of knowledge supported by many one-arm, non-randomised, one-center trials. Finally the randomised trial showing that AHSCT in better in MS than DMDs. Full text here: https://www.ncbi.nlm.nih.gov/pubmed/30644983
- AHSCT is a standard of care of RRMS
- Wykłady na kursie specjalizacyjnym – transplantologia
- AHSCT is better choice than DMDs in MS as a treatment of cases progressing after first line treatment – multicenter randomised trial.
- CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML
- Complementary Medicine (alternative medicine) not so good for cancer patients